HealthDay News — Blood levels of ghrelin may be a predictor of executive function impairment in patients with type 2 diabetes, according to a study published in the Journal of Diabetes Investigation.
Siting Chen, MD, from Anhui Medical University in Hefei, China, and colleagues analyzed ghrelin levels in blood samples from 212 patients with type 2 diabetes and 158 controls.
The researchers found that age, education year, duration of diabetes, fasting blood glucose, glycated hemoglobin, hypertension, and waist-to-hip ratio were correlated with total Montreal Cognitive Assessment (MoCA) scores in the type 2 diabetes group. There was no association between ghrelin level and total MoCA score in patients with type 2 diabetes. However, ghrelin was a significant predictor for executive function impairment in patients with type 2 diabetes measured by the Wisconsin Card Sorting Test.
“The level of serum ghrelin might be a biomarker of executive function and become a strong predictor of executive function impairment in patients with type 2 diabetes,” the researchers wrote. “Ghrelin might have a potential protective effect against cognitive function impairment in type 2 diabetic patients.”
Disclosures: The authors declare no conflicts of interest.
- Chen S, Zuo X, Li Y, et al. Ghrelin is a possible new predictor associated with executive function in patients with type 2 diabetes mellitus. J Diabetes Investig. 2016 Sep 30. doi:10.1111/jdi.12580 [Epub ahead of print]